APA (7th ed.) Citation

P, A., C, A., F, G., S, C., S, R., P, R., & O, M. (2021). Humanized anti CD-20 as an alternative in chronic management of relapsing thrombotic thrombocytopenic microangiopathy resistant to rituximab due to anti chimeric antibody. International journal of hematology, 113(3), 456. https://doi.org/10.1007/s12185-020-03020-7

Chicago Style (17th ed.) Citation

P, Ahmadpoor, Aglae C, Garo F, Cariou S, Renaud S, Reboul P, and Moranne O. "Humanized Anti CD-20 as an Alternative in Chronic Management of Relapsing Thrombotic Thrombocytopenic Microangiopathy Resistant to Rituximab Due to Anti Chimeric Antibody." International Journal of Hematology 113, no. 3 (2021): 456. https://doi.org/10.1007/s12185-020-03020-7.

MLA (9th ed.) Citation

P, Ahmadpoor, et al. "Humanized Anti CD-20 as an Alternative in Chronic Management of Relapsing Thrombotic Thrombocytopenic Microangiopathy Resistant to Rituximab Due to Anti Chimeric Antibody." International Journal of Hematology, vol. 113, no. 3, 2021, p. 456, https://doi.org/10.1007/s12185-020-03020-7.